Innate Pharma Stock Price History
IPHA Stock | USD 1.79 0.03 1.70% |
If you're considering investing in Innate Stock, it is important to understand the factors that can impact its price. As of today, the current price of Innate Pharma stands at 1.79, as last reported on the 31st of January, with the highest price reaching 1.81 and the lowest price hitting 1.74 during the day. Innate Pharma appears to be abnormally volatile, given 3 months investment horizon. Innate Pharma holds Efficiency (Sharpe) Ratio of 0.0476, which attests that the entity had a 0.0476 % return per unit of risk over the last 3 months. By evaluating Innate Pharma's technical indicators, you can evaluate if the expected return of 0.68% is justified by implied risk. Please utilize Innate Pharma's Risk Adjusted Performance of 0.0492, downside deviation of 7.64, and Market Risk Adjusted Performance of 1.21 to validate if our risk estimates are consistent with your expectations.
Innate Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Innate |
Sharpe Ratio = 0.0476
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | IPHA | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
14.22 actual daily | 96 96% of assets are less volatile |
Expected Return
0.68 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Innate Pharma is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Innate Pharma by adding it to a well-diversified portfolio.
Innate Pharma Stock Price History Chart
There are several ways to analyze Innate Stock price data. The simplest method is using a basic Innate candlestick price chart, which shows Innate Pharma price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
Highest Price | December 13, 2024 | 3.02 |
Lowest Price | November 15, 2024 | 1.44 |
Innate Pharma January 31, 2025 Stock Price Synopsis
Various analyses of Innate Pharma's daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Innate Stock. It can be used to describe the percentage change in the price of Innate Pharma from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Innate Stock.Innate Pharma Price Daily Balance Of Power | 0.43 | |
Innate Pharma Price Rate Of Daily Change | 1.02 | |
Innate Pharma Price Action Indicator | 0.03 |
Innate Pharma January 31, 2025 Stock Price Analysis
Innate Stock Price History Data
The price series of Innate Pharma for the period between Sat, Nov 2, 2024 and Fri, Jan 31, 2025 has a statistical range of 1.58 with a coefficient of variation of 14.82. Under current investment horizon, the daily prices are spread out with arithmetic mean of 1.8. The median price for the last 90 days is 1.79.Open | High | Low | Close | Volume | ||
01/31/2025 | 1.76 | 1.81 | 1.74 | 1.79 | ||
01/30/2025 | 1.76 | 1.81 | 1.74 | 1.79 | 15,348 | |
01/29/2025 | 1.74 | 1.80 | 1.71 | 1.76 | 21,796 | |
01/28/2025 | 1.77 | 1.83 | 1.70 | 1.76 | 45,581 | |
01/27/2025 | 1.85 | 1.92 | 1.70 | 1.80 | 385,400 | |
01/24/2025 | 1.75 | 1.77 | 1.67 | 1.77 | 20,437 | |
01/23/2025 | 1.74 | 1.74 | 1.63 | 1.67 | 21,083 | |
01/22/2025 | 1.78 | 1.78 | 1.76 | 1.77 | 4,614 | |
01/21/2025 | 1.74 | 1.77 | 1.74 | 1.77 | 11,492 | |
01/17/2025 | 1.73 | 1.74 | 1.65 | 1.69 | 13,723 | |
01/16/2025 | 1.73 | 1.75 | 1.67 | 1.67 | 31,476 | |
01/15/2025 | 1.80 | 1.80 | 1.60 | 1.70 | 100,189 | |
01/14/2025 | 1.82 | 1.83 | 1.75 | 1.79 | 12,198 | |
01/13/2025 | 1.79 | 1.87 | 1.78 | 1.82 | 29,616 | |
01/10/2025 | 1.83 | 1.83 | 1.74 | 1.77 | 74,986 | |
01/08/2025 | 1.87 | 1.87 | 1.64 | 1.83 | 38,403 | |
01/07/2025 | 1.89 | 1.89 | 1.83 | 1.86 | 15,159 | |
01/06/2025 | 1.92 | 1.95 | 1.85 | 1.88 | 80,226 | |
01/03/2025 | 1.90 | 1.94 | 1.80 | 1.87 | 25,676 | |
01/02/2025 | 1.94 | 1.94 | 1.87 | 1.87 | 38,367 | |
12/31/2024 | 1.94 | 1.96 | 1.77 | 1.84 | 49,365 | |
12/30/2024 | 2.09 | 2.09 | 1.81 | 1.95 | 101,583 | |
12/27/2024 | 2.11 | 2.14 | 2.04 | 2.11 | 33,408 | |
12/26/2024 | 2.07 | 2.12 | 2.03 | 2.11 | 41,712 | |
12/24/2024 | 2.06 | 2.08 | 2.03 | 2.06 | 24,122 | |
12/23/2024 | 2.04 | 2.15 | 2.01 | 2.10 | 37,962 | |
12/20/2024 | 2.08 | 2.10 | 2.03 | 2.05 | 48,484 | |
12/19/2024 | 2.15 | 2.18 | 2.08 | 2.16 | 43,751 | |
12/18/2024 | 2.19 | 2.36 | 2.11 | 2.16 | 156,594 | |
12/17/2024 | 2.12 | 2.31 | 2.12 | 2.15 | 196,236 | |
12/16/2024 | 2.44 | 2.67 | 2.07 | 2.37 | 957,982 | |
12/13/2024 | 1.50 | 3.51 | 1.47 | 3.02 | 13,573,101 | |
12/12/2024 | 1.57 | 1.64 | 1.54 | 1.55 | 126,246 | |
12/11/2024 | 1.66 | 1.73 | 1.52 | 1.69 | 301,555 | |
12/10/2024 | 1.80 | 1.85 | 1.65 | 1.80 | 760,334 | |
12/09/2024 | 1.84 | 1.94 | 1.57 | 1.90 | 13,078,896 | |
12/06/2024 | 1.62 | 1.62 | 1.43 | 1.47 | 40,950 | |
12/05/2024 | 1.46 | 1.46 | 1.43 | 1.45 | 21,634 | |
12/04/2024 | 1.51 | 1.51 | 1.41 | 1.45 | 14,900 | |
12/03/2024 | 1.51 | 1.51 | 1.51 | 1.51 | 512.00 | |
12/02/2024 | 1.56 | 1.56 | 1.45 | 1.46 | 10,711 | |
11/29/2024 | 1.49 | 1.55 | 1.49 | 1.54 | 3,508 | |
11/27/2024 | 1.59 | 1.59 | 1.50 | 1.50 | 6,902 | |
11/26/2024 | 1.48 | 1.50 | 1.48 | 1.50 | 9,682 | |
11/25/2024 | 1.56 | 1.57 | 1.45 | 1.45 | 69,405 | |
11/22/2024 | 1.60 | 1.70 | 1.54 | 1.63 | 7,993 | |
11/21/2024 | 1.65 | 1.70 | 1.56 | 1.70 | 1,303 | |
11/20/2024 | 1.60 | 1.70 | 1.60 | 1.69 | 7,669 | |
11/19/2024 | 1.55 | 1.61 | 1.48 | 1.49 | 11,599 | |
11/18/2024 | 1.45 | 1.66 | 1.29 | 1.53 | 41,648 | |
11/15/2024 | 1.60 | 1.66 | 1.44 | 1.44 | 20,125 | |
11/14/2024 | 1.65 | 1.68 | 1.62 | 1.67 | 5,758 | |
11/13/2024 | 1.70 | 1.70 | 1.68 | 1.68 | 4,018 | |
11/12/2024 | 1.75 | 1.91 | 1.75 | 1.90 | 8,941 | |
11/11/2024 | 1.69 | 2.00 | 1.68 | 1.85 | 7,438 | |
11/08/2024 | 1.57 | 1.87 | 1.57 | 1.84 | 7,075 | |
11/07/2024 | 1.82 | 1.85 | 1.71 | 1.84 | 3,848 | |
11/06/2024 | 2.06 | 2.06 | 2.06 | 2.06 | 348.00 | |
11/05/2024 | 1.73 | 1.78 | 1.73 | 1.78 | 4,049 | |
11/04/2024 | 1.94 | 1.94 | 1.80 | 1.83 | 2,136 | |
11/01/2024 | 1.83 | 1.91 | 1.83 | 1.88 | 6,627 |
About Innate Pharma Stock history
Innate Pharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Innate is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Innate Pharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Innate Pharma stock prices may prove useful in developing a viable investing in Innate Pharma
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company was incorporated in 1999 and is headquartered in Marseille, France. Innate Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 213 people.
Innate Pharma Stock Technical Analysis
Innate Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run ETF Categories Now
ETF CategoriesList of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
All Next | Launch Module |
Innate Pharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Innate Pharma's price direction in advance. Along with the technical and fundamental analysis of Innate Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Innate to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | 0.0492 | |||
Jensen Alpha | 0.6173 | |||
Total Risk Alpha | (0.86) | |||
Sortino Ratio | 0.0755 | |||
Treynor Ratio | 1.2 |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |